Thomas Burroughs

Dr. Thomas Burroughs

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2007 in Transplantation
Verified
Journal Article
Closed access
TBThomas Burroughs
Thomas Burroughs
JSJason Swindle
Jason Swindle
STSteven Takemoto
Steven Takemoto
KLKrista L. Lentine
Krista L. Lentine
GMGerardo Machnicki
Gerardo Machnicki
MSMark A. Schnitzler
Mark A. Schnitzler
Background. Data are scarce regarding the incidence and risk factors for complications of new-onset diabetes mellitus (NODM) in renal transplant patients. Methods. United States Renal Data System (USRDS) data from primary renal transplant recipients during 1995–2001 who developed NODM was used to examine diabetic complications over the first three years posttransplant. Prognostic models were used to evaluate patient characteristics and treatment choices associated with risk of each class of complications. Propensity scores for choice of calcineurin inhibitor were included in multivariate analyses. Results. The analysis included 21,489 patients, of whom 4,105 developed NODM by 3 years posttransplant. One or more NODM complications developed in 2,393 patients (58.3% of all patients with NODM), comprising ketoacidosis (334, 8.1%), hyperosmolarity (131, 3.2%), renal complications (1,286, 31.3%), ophthalmic complications (340, 8.3%), neurological complications (665, 16.2%), peripheral circulatory disorders (170, 4.1%) and hypoglycemia/shock (301, 7.3%). Complications developed within a mean of 500 to 600 days from diagnosis of NODM. Multivariate analysis showed that increased recipient age, higher body mass index, African-American race, hepatitis C infection, hypertension as cause of end-stage renal disease, cold ischemia ≥30 hours, and use of tacrolimus each increased risk of complications. Conclusion. NODM is associated with similar complications to those seen in the general population, but these appear to develop at an accelerated rate. Obesity and use of tacrolimus are the only modifiable factors that appear to affect risk of NODM or its complications.

1 January 2007 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Closed access
TBThomas Burroughs
Thomas Burroughs
AWAmy D. Waterman
Amy D. Waterman
TGThomas H. Gallagher
Thomas H. Gallagher
BWBrian Waterman
Brian Waterman
DJDonna B. Jeffe
Donna B. Jeffe
VFVictoria J. Fraser
Victoria J. Fraser

1 January 2005 in Academic Emergency Medicine
Verified
Journal Article
Closed access
TBThomas Burroughs
Thomas Burroughs

20 December 2022 in American Journal of Gastroenterology
Verified
Journal Article
Open access
SMSatish Munigala
Satish Munigala
SASami Almaskeen
Sami Almaskeen
DSDivya S. Subramaniam
Divya S. Subramaniam
SBSriya Bandi
Sriya Bandi
BBBenjamin Bowe
Benjamin Bowe
BABanke Agarwal
Banke Agarwal
INTRODUCTION: In animal models, inflammation caused by experimental acute pancreatitis (AP) promotes pancreatic carcinogenesis that is preventable by suppressing inflammation. Recent studies noted higher long-term risk of pancreatic ductal adenocarcinoma (PDAC) after AP. In this study, we evaluated whether the long-term PDAC risk after AP was influenced by the etiology of AP, number of recurrences, and if it was because of progression to chronic pancreatitis (CP). METHODS: This retrospective study used nationwide Veterans Administration database spanning 1999–2015. A 2-year washout period was applied to exclude patients with preexisting AP and PDAC. PDAC risk was estimated in patients with AP without (AP group) and with underlying CP (APCP group) and those with CP alone (CP group) and compared with PDAC risk in patients in a control group, respectively, using cause-specific hazards model. RESULTS: The final cohort comprised 7,147,859 subjects (AP-35,550 and PDAC-16,475). The cumulative PDAC risk 3–10 years after AP was higher than in controls (0.61% vs 0.18%), adjusted hazard ratio (1.7 [1.4–2.0], P < 0.001). Adjusted hazard ratio was 1.5 in AP group, 2.4 in the CP group, and 3.3 in APCP group. PDAC risk increased with the number of AP episodes. Elevated PDAC risk after AP was not influenced by the etiology of AP (gallstones, smoking, or alcohol). DISCUSSION: There is a higher PDAC risk 3–10 years after AP irrespective of the etiology of AP, increases with the number of episodes of AP and is additive to higher PDAC risk because of CP.

1 March 2005 in The Joint Commission Journal on Quality and Patient Safety
Verified
Journal Article
Closed access
TBThomas Burroughs
Thomas Burroughs
BWBrian M. Waterman
Brian M. Waterman
DGDebra Gilin
Debra Gilin
DADavid Adams
David Adams
JMJamie McCollegan
Jamie McCollegan
JCJanie Cira
Janie Cira

1 May 2007 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
TBThomas Burroughs
Thomas Burroughs
KLKrista L. Lentine
Krista L. Lentine
STSteve K. Takemoto
Steve K. Takemoto
JSJason Swindle
Jason Swindle
GMGerardo Machnicki
Gerardo Machnicki
MSMark A. Schnitzler
Mark A. Schnitzler
Risk for new-onset diabetes (NOD) after renal transplantation is higher with tacrolimus (Tac) than with cyclosporine (CsA), but the extent to which the diabetogenic effect of Tac is dosage dependent or steroid dependent remains uncertain. Patients who received a transplant between 1995 and 2002 were drawn from the United Network for Organ Sharing registry and prescription records and NOD diagnoses from Medicare claims, both provided by the United States Renal Data System. Patients were divided into six groups of steroid and Tac doses at 30 d after transplantation and referenced against CsA. Relative hazards of NOD with Cox proportional hazards regression were estimated incorporating propensity scores for Tac and nonimmunosuppressive factors related to NOD. A total of 8839 patients with valid immunosuppression records and without pretransplantation evidence of diabetes were included in the study. Unadjusted, cumulative, NOD incidence 1 yr after transplantation was 14.6% with CsA and 22.2% with Tac and at 3 yr after transplantation was 23.4% with CsA and 32.9% with Tac (P < 0.0001). Neither higher CsA nor higher steroid dosages were associated with NOD in CsA-treated patients. However, NOD hazard was significantly higher with Tac than with CsA in all six steroid/Tac dosing groups, including the cohort with the lowest dosages of Tac (dosage thresholds at 30 d after transplantation <0.12 mg/kg per d [mean 0.07 mg/kg per d] and steroids (<0.75 mg/kg per d; hazard ratio 1.28; 95% confidence interval 1.10 to 1.48; P = 0.0012). Whereas the incidence of NOD is greatest with high Tac dosages, the increased risk versus CsA is sustained with lower Tac dosages. Higher steroid dosages increase the early diabetogenic effect of Tac but not of CsA.